Information Provided By: 
Fly News Breaks for February 28, 2018
SRDX
Feb 28, 2018 | 09:11 EDT
Barrington analyst Michael Petusky upgraded Surmodics to Outperform with a $38 price target. The company's agreement with Abbott (ABT) is "perhaps the most significant news" for Surmodics in over 10 years and represents a "major validation" of the management team's view that the Surveil drug-coated balloon could be a "true next generation product in the space," Petusky tells investors in a research note.
News For SRDX From the Last 2 Days
There are no results for your query SRDX
